-
Something wrong with this record ?
LYmphoid NeXt-Generation Sequencing (LYNX) Panel: A Comprehensive Capture-Based Sequencing Tool for the Analysis of Prognostic and Predictive Markers in Lymphoid Malignancies
V. Navrkalova, K. Plevova, J. Hynst, K. Pal, A. Mareckova, T. Reigl, H. Jelinkova, Z. Vrzalova, K. Stranska, S. Pavlova, A. Panovska, A. Janikova, M. Doubek, J. Kotaskova, S. Pospisilova
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Free Medical Journals
from 1999
Freely Accessible Science Journals
from 1999 to 1 year ago
- MeSH
- Chromosome Aberrations MeSH
- Molecular Diagnostic Techniques MeSH
- Genetic Predisposition to Disease * MeSH
- Genetic Variation MeSH
- Genomics methods MeSH
- Humans MeSH
- Leukemia, Lymphoid diagnosis genetics MeSH
- Lymphoma diagnosis genetics MeSH
- INDEL Mutation MeSH
- Biomarkers, Tumor * MeSH
- Prognosis MeSH
- Translocation, Genetic MeSH
- DNA Copy Number Variations MeSH
- Computational Biology methods MeSH
- High-Throughput Nucleotide Sequencing * methods MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
B-cell neoplasms represent a clinically heterogeneous group of hematologic malignancies with considerably diverse genomic architecture recently endorsed by next-generation sequencing (NGS) studies. Because multiple genetic defects have a potential or confirmed clinical impact, a tendency toward more comprehensive testing of diagnostic, prognostic, and predictive markers is desired. This study introduces the design, validation, and implementation of an integrative, custom-designed, capture-based NGS panel titled LYmphoid NeXt-generation sequencing (LYNX) for the analysis of standard and novel molecular markers in the most common lymphoid neoplasms (chronic lymphocytic leukemia, acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma). A single LYNX test provides the following: i) accurate detection of mutations in all coding exons and splice sites of 70 lymphoma-related genes with a sensitivity of 5% variant allele frequency, ii) reliable identification of large genome-wide (≥6 Mb) and recurrent chromosomal aberrations (≥300 kb) in at least 20% of the clonal cell fraction, iii) the assessment of immunoglobulin and T-cell receptor gene rearrangements, and iv) lymphoma-specific translocation detection. Dedicated bioinformatic pipelines were designed to detect all markers mentioned above. The LYNX panel represents a comprehensive, up-to-date tool suitable for routine testing of lymphoid neoplasms with research and clinical applicability. It allows a wide adoption of capture-based targeted NGS in clinical practice and personalized management of patients with lymphoproliferative diseases.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22012321
- 003
- CZ-PrNML
- 005
- 20220506130608.0
- 007
- ta
- 008
- 220425s2021 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jmoldx.2021.05.007 $2 doi
- 035 __
- $a (PubMed)34082072
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Navrkalova, Veronika $u Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic
- 245 10
- $a LYmphoid NeXt-Generation Sequencing (LYNX) Panel: A Comprehensive Capture-Based Sequencing Tool for the Analysis of Prognostic and Predictive Markers in Lymphoid Malignancies / $c V. Navrkalova, K. Plevova, J. Hynst, K. Pal, A. Mareckova, T. Reigl, H. Jelinkova, Z. Vrzalova, K. Stranska, S. Pavlova, A. Panovska, A. Janikova, M. Doubek, J. Kotaskova, S. Pospisilova
- 520 9_
- $a B-cell neoplasms represent a clinically heterogeneous group of hematologic malignancies with considerably diverse genomic architecture recently endorsed by next-generation sequencing (NGS) studies. Because multiple genetic defects have a potential or confirmed clinical impact, a tendency toward more comprehensive testing of diagnostic, prognostic, and predictive markers is desired. This study introduces the design, validation, and implementation of an integrative, custom-designed, capture-based NGS panel titled LYmphoid NeXt-generation sequencing (LYNX) for the analysis of standard and novel molecular markers in the most common lymphoid neoplasms (chronic lymphocytic leukemia, acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma). A single LYNX test provides the following: i) accurate detection of mutations in all coding exons and splice sites of 70 lymphoma-related genes with a sensitivity of 5% variant allele frequency, ii) reliable identification of large genome-wide (≥6 Mb) and recurrent chromosomal aberrations (≥300 kb) in at least 20% of the clonal cell fraction, iii) the assessment of immunoglobulin and T-cell receptor gene rearrangements, and iv) lymphoma-specific translocation detection. Dedicated bioinformatic pipelines were designed to detect all markers mentioned above. The LYNX panel represents a comprehensive, up-to-date tool suitable for routine testing of lymphoid neoplasms with research and clinical applicability. It allows a wide adoption of capture-based targeted NGS in clinical practice and personalized management of patients with lymphoproliferative diseases.
- 650 12
- $a nádorové biomarkery $7 D014408
- 650 _2
- $a chromozomální aberace $7 D002869
- 650 _2
- $a výpočetní biologie $x metody $7 D019295
- 650 _2
- $a variabilita počtu kopií segmentů DNA $7 D056915
- 650 12
- $a genetická predispozice k nemoci $7 D020022
- 650 _2
- $a genetická variace $7 D014644
- 650 _2
- $a genomika $x metody $7 D023281
- 650 12
- $a vysoce účinné nukleotidové sekvenování $x metody $7 D059014
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mutace INDEL $7 D054643
- 650 _2
- $a lymfoidní leukemie $x diagnóza $x genetika $7 D007945
- 650 _2
- $a lymfom $x diagnóza $x genetika $7 D008223
- 650 _2
- $a diagnostické techniky molekulární $7 D025202
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a translokace genetická $7 D014178
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Plevova, Karla $u Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Institute of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Hynst, Jakub $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Pal, Karol $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine II - Hematology and Oncology, University Medical Center Schleswig-Holstein, Kiel, Germany
- 700 1_
- $a Mareckova, Andrea $u Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Reigl, Tomas $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Jelinkova, Hana $u Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Vrzalova, Zuzana $u Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Stranska, Kamila $u Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Pavlova, Sarka $u Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Panovska, Anna $u Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Janikova, Andrea $u Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Doubek, Michael $u Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Institute of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Kotaskova, Jana $u Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Pospisilova, Sarka $u Department of Internal Medicine - Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Institute of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic. Electronic address: sarka.pospisilova@ceitec.muni.cz
- 773 0_
- $w MED00012712 $t The Journal of molecular diagnostics : JMD $x 1943-7811 $g Roč. 23, č. 8 (2021), s. 959-974
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34082072 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130600 $b ABA008
- 999 __
- $a ok $b bmc $g 1789768 $s 1163522
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 23 $c 8 $d 959-974 $e 20210601 $i 1943-7811 $m The Journal of molecular diagnostics $n J Mol Diagn $x MED00012712
- LZP __
- $a Pubmed-20220425